Receptor subtype and outcome of breast cancer - Single-center experience from North India

Aims/Objectives: In resource-limited settings, data regarding the impact of molecular/receptor subtypes on breast cancer (BC) are sparse. In this single-center retrospective study from north India, we analyze the outcomes of various molecular subtypes of BC. Materials and Methods: Females with biopsy-proven BC who were treated at our State Cancer Institute from 2014-2018 were included. Data regarding clinicopathological parameters and follow-up details were evaluated. For data analysis, cancers were categorized into 4 subtypes: HR(+)HER2(-), HR(+)HER2(+), HR(-)HER2(+), and HR-HER2(-). Results: Among 944 patients included, HR(+)HER2(-) (49.1%) and HR(+)HER2(+) (13.1%) were the most and least common subtypes, respectively. The receptor subtype significantly impacted overall survival (OS). HR(+)HER2(-) cancers had the best outcomes while HR(-)HER2(-) cancers fared worst (3-yr OS of 94.3% and 69.1%, respectively). On subgroup analysis, the molecular subtype continued to significantly impact OS in patients with tumor grades II and III, disease stages II and III, and age groups of <40 and 40-60 years, respectively (HR(-)HER2(-) cancers had the lowest cumulative survival in each subgroup). In patients with metastatic BC, all molecular subtypes except HR(+)HER2(-) had a dismal prognosis. Conclusions: Overall and across various subgroups, patients with triple-negative BC had the poorest outcomes. Ensuring optimal treatment utilization including affordable access to personalized tailored therapy is the need of the hour to improve long-term outcomes in these patients.